Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs

• Published in: Blood advances Vol. 7; no. 7; pp. 1117 - 1129
• Main Authors: Fletcher, Rochelle E., Nunes, Natalia S., Patterson, Michael T., Vinod, Natasha, Khan, Shanzay M., Mendu, Suresh K., Li, Xianghong, de Paula Pohl, Alessandra, Wachsmuth, Lucas P., Choo-Wosoba, Hyoyoung, Eckhaus, Michael A., Venzon, David J., Kanakry, Christopher G.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 11.04.2023; The American Society of Hematology
• Subjects: Animals; Cyclophosphamide - therapeutic use; Graft vs Host Disease - pathology; Hematopoietic Stem Cell Transplantation - methods; Mice; Myeloid-Derived Suppressor Cells - pathology; T-Lymphocytes, Regulatory; Transplantation
• ISSN: 2473-9529; 2473-9537
• DOI: 10.1182/bloodadvances.2022007026

•PTCy prevents induction of GVHD from subsequent cell infusion via an indirect effect on Foxp3+ regulatory T cells.•PTCy modifies the immune environment to expand functional MDSCs, which augment regulatory T-cell recovery. [Display omitted] Posttransplantation cyclophosphamide (PTCy), given on days +3 and +4, reduces graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT), but its immunologic underpinnings are not fully understood. In a T-cell–replete, major histocompatibility complex-haploidentical murine HCT model (B6C3F1→B6D2F1), we previously showed that PTCy rapidly induces suppressive mechanisms sufficient to prevent GVHD induction by non-PTCy–exposed donor splenocytes infused on day +5. Here, in PTCy-treated mice, we found that depleting Foxp3+ regulatory T cells (Tregs) in the initial graft but not the day +5 splenocytes did not worsen GVHD, yet depleting Tregs in both cellular compartments led to fatal GVHD induced by the day +5 splenocytes. Hence, Tregs were necessary to control GVHD induced by new donor cells, but PTCy’s impact on Tregs appeared to be indirect. Therefore, we hypothesized that myeloid-derived suppressor cells (MDSCs) play a complementary role. Functionally suppressive granulocytic and monocytic MDSCs were increased in percentages in PTCy-treated mice, and MDSC percentages were increased after administering PTCy to patients undergoing HLA-haploidentical HCT. PTCy increased colony-stimulating factors critical for MDSC development and rapidly promoted the generation of MDSCs from bone marrow precursors. MDSC reduction via anti-Gr1 treatment in murine HCT did not worsen histopathologic GVHD but resulted in decreased Tregs and inferior survival. The clinical implications of these findings, including the potential impact of expanded MDSCs after PTCy on engraftment and cytokine release syndrome, remain to be elucidated. Moreover, the indirect effect that PTCy has on Tregs, which in turn play a necessary role in GVHD prevention by initially transplanted or subsequently infused T cells, requires further investigation.